These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28006087)

  • 21. HER2-targeted therapies for salivary gland cancers.
    Filippini DM; Pagani R; Tober N; Lorini L; Riefolo M; Molinari G; Burato A; Alfieri S; Bossi P; Presutti L
    Oral Oncol; 2024 Jan; 148():106612. PubMed ID: 38016228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Clinical Utilisation and Duration of Treatment with HER2-Directed Therapies in HER2-Positive Recurrent or Metastatic Salivary Gland Cancers.
    Haigh JE; Patel K; Rack S; Jiménez-Labaig P; Betts G; Harrington KJ; Metcalf R
    Curr Oncol; 2024 Sep; 31(9):5652-5661. PubMed ID: 39330047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The expression assessment of the estrogen, progesterone and HER2 receptors in selected malignant tumors of the salivary glands].
    Golusiński W; Wegner A; Trzeciak P; Golusiński P; Sówka M; Kopczyński A; Bromboszcz M; Marszałek A
    Otolaryngol Pol; 2013; 67(5):245-51. PubMed ID: 24021827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Partial response to RC-48 as palliative treatment in a patient with locallocally advanced carcinoma ex pleomorphic adenoma harboring a HER2 mutation: a case report.
    Yu W; Ding C; Li K
    Oral Oncol; 2023 Nov; 146():106541. PubMed ID: 37595449
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of trastuzumab in the management of salivary ductal carcinomas.
    Perissinotti AJ; Lee Pierce M; Pace MB; El-Naggar A; Kies MS; Kupferman M
    Anticancer Res; 2013 Jun; 33(6):2587-91. PubMed ID: 23749912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A low percentage of HER-2 amplification whereas indicates poor prognosis in salivary carcinoma ex pleomorphic adenoma: a study of 140 cases.
    Xia L; Hu Y; Li J; Gu T; Zhang C; Wang L; Tian Z
    J Oral Pathol Med; 2017 Mar; 46(3):167-174. PubMed ID: 27423271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Salivary duct carcinoma--a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression.
    Skálová A; Stárek ; Kucerová V; Szépe P; Plank L
    Pathol Res Pract; 2001; 197(9):621-6. PubMed ID: 11569926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A case of metastatic salivary duct carcinoma successfully treated with trastuzumab-based targeted therapy].
    Iguchi F; Taniguchi Z; Kusano J; Takahashi Y; Murai N
    Nihon Jibiinkoka Gakkai Kaiho; 2014 Aug; 117(8):1108-14. PubMed ID: 25255650
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.
    Luk PP; Weston JD; Yu B; Selinger CI; Ekmejian R; Eviston TJ; Lum T; Gao K; Boyer M; O'Toole SA; Clark JR; Gupta R
    Head Neck; 2016 Apr; 38 Suppl 1():E1838-47. PubMed ID: 26699379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
    Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A
    Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eribulin in combination with HER2-targeted antibodies for successful treatment of metastatic salivary duct carcinoma: A report of two cases.
    Fujimi A; Nagamachi Y; Yamauchi N; Nishisato T; Murase K; Takada K; Tsujiwaki M; Sugita S; Hasegawa T; Kato J
    Oral Oncol; 2021 Sep; 120():105287. PubMed ID: 33858766
    [No Abstract]   [Full Text] [Related]  

  • 32. The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers.
    Hanna GJ; Bae JE; Lorch JH; Haddad RI; Jo VY; Schoenfeld JD; Margalit DN; Tishler RB; Goguen LA; Annino DJ; Chau NG
    Oncologist; 2020 Jul; 25(7):598-608. PubMed ID: 32310325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histological, immunohistological and molecular characteristics of intraductal precursor of carcinoma ex pleomorphic adenoma support a multistep carcinogenic process.
    Ihrler S; Guntinas-Lichius O; Agaimy A; Wolf A; Mollenhauer M
    Virchows Arch; 2017 Jun; 470(6):601-609. PubMed ID: 28353089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Survival benefit of anti-HER2 therapy after whole-brain radiotherapy in HER2-positive breast cancer patients with brain metastasis.
    Zhang Q; Chen J; Yu X; Cai G; Yang Z; Cao L; Hu C; Guo X; Sun J; Chen J
    Breast Cancer; 2016 Sep; 23(5):732-9. PubMed ID: 26267412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.
    Sartore-Bianchi A; Trusolino L; Martino C; Bencardino K; Lonardi S; Bergamo F; Zagonel V; Leone F; Depetris I; Martinelli E; Troiani T; Ciardiello F; Racca P; Bertotti A; Siravegna G; Torri V; Amatu A; Ghezzi S; Marrapese G; Palmeri L; Valtorta E; Cassingena A; Lauricella C; Vanzulli A; Regge D; Veronese S; Comoglio PM; Bardelli A; Marsoni S; Siena S
    Lancet Oncol; 2016 Jun; 17(6):738-746. PubMed ID: 27108243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clear cell myoepithelial carcinoma of salivary glands showing EWSR1 rearrangement: molecular analysis of 94 salivary gland carcinomas with prominent clear cell component.
    Skálová A; Weinreb I; Hyrcza M; Simpson RH; Laco J; Agaimy A; Vazmitel M; Majewska H; Vanecek T; Talarčik P; Manajlovic S; Losito SN; Šteiner P; Klimkova A; Michal M
    Am J Surg Pathol; 2015 Mar; 39(3):338-48. PubMed ID: 25581728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2 expression in salivary gland carcinomas: dependence on histological subtype.
    Glisson B; Colevas AD; Haddad R; Krane J; El-Naggar A; Kies M; Costello R; Summey C; Arquette M; Langer C; Amrein PC; Posner M
    Clin Cancer Res; 2004 Feb; 10(3):944-6. PubMed ID: 14871971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy.
    Prat A; Parera M; Reyes V; Peralta S; Cedrés S; Andreu J; Huguet P; del Campo JM
    Head Neck; 2008 May; 30(5):680-3. PubMed ID: 17972317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of ado-trastuzumab emtansine (T-DM1) in HER2 positive salivary gland tumour with brain metastasis.
    Dhamne N; Koyyala VPB; Chougule S; Pawar S
    BMJ Case Rep; 2022 May; 15(5):. PubMed ID: 35641086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness.
    Sugano S; Mukai K; Tsuda H; Hirohashi S; Furuya S; Shimosato Y; Ebihara S; Takeyama I
    Laryngoscope; 1992 Aug; 102(8):923-7. PubMed ID: 1353853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.